Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALDX NASDAQ:ETHZ NASDAQ:JSPR NASDAQ:QTTB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$1.76+2.0%$2.75$1.07▼$6.18$105.86M1.162.45 million shs927,987 shsETHZFlag Ship Acquisition$4.91-10.6%$3.22$0.70▼$17.46$93.35M1.176.44 million shs432,520 shsJSPRJasper Therapeutics$0.96-1.1%$1.08$0.62▼$7.19$26.80M3.07577,818 shs149,301 shsQTTBQ32 Bio$5.21+1.4%$5.86$1.35▼$8.05$81.43M-0.05257,807 shs213,876 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics+8.18%+9.55%+3.61%-67.05%-36.30%ETHZFlag Ship Acquisition-6.15%+1.29%+99.64%+57.76%+548,999,900.00%JSPRJasper Therapeutics+3.87%+3.94%+40.45%-29.98%-81.52%QTTBQ32 Bio+1.98%-10.14%-19.44%+27.86%+229.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$1.76+2.0%$2.75$1.07▼$6.18$105.86M1.162.45 million shs927,987 shsETHZFlag Ship Acquisition$4.91-10.6%$3.22$0.70▼$17.46$93.35M1.176.44 million shs432,520 shsJSPRJasper Therapeutics$0.96-1.1%$1.08$0.62▼$7.19$26.80M3.07577,818 shs149,301 shsQTTBQ32 Bio$5.21+1.4%$5.86$1.35▼$8.05$81.43M-0.05257,807 shs213,876 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics+8.18%+9.55%+3.61%-67.05%-36.30%ETHZFlag Ship Acquisition-6.15%+1.29%+99.64%+57.76%+548,999,900.00%JSPRJasper Therapeutics+3.87%+3.94%+40.45%-29.98%-81.52%QTTBQ32 Bio+1.98%-10.14%-19.44%+27.86%+229.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDXAldeyra Therapeutics 2.00Hold$5.50213.39% UpsideETHZFlag Ship Acquisition 1.00SellN/AN/AJSPRJasper Therapeutics 2.42Hold$19.881,978.97% UpsideQTTBQ32 Bio 2.67Moderate Buy$13.00149.33% UpsideCurrent Analyst Ratings BreakdownLatest JSPR, ALDX, ETHZ, and QTTB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026QTTBQ32 Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.004/21/2026JSPRJasper Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/23/2026JSPRJasper Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral3/18/2026ALDXAldeyra Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$10.00 ➝ $2.003/17/2026ALDXAldeyra Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy3/12/2026QTTBQ32 Bio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy3/10/2026QTTBQ32 Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.002/25/2026QTTBQ32 Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$13.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDXAldeyra TherapeuticsN/AN/AN/AN/A$0.74 per shareN/AETHZFlag Ship Acquisition$4.11M22.71N/AN/A$29.12 per share0.17JSPRJasper TherapeuticsN/AN/AN/AN/A$0.15 per shareN/AQTTBQ32 Bio$53.74M1.52$1.57 per share3.32$3.41 per share1.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDXAldeyra Therapeutics-$33.85M-$0.57N/AN/AN/AN/A-63.75%-41.27%5/13/2026 (Estimated)ETHZFlag Ship Acquisition-$6.17M-$159.65N/AN/AN/AN/A-185.71%-83.12%N/AJSPRJasper Therapeutics-$75.80M-$4.60N/AN/AN/AN/A-372.18%-153.67%5/11/2026 (Estimated)QTTBQ32 Bio$29.82M$2.302.27N/AN/AN/A988.60%27.32%5/7/2026 (Estimated)Latest JSPR, ALDX, ETHZ, and QTTB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ALDXAldeyra Therapeutics-$0.13N/AN/AN/AN/AN/A5/11/2026Q1 2026JSPRJasper Therapeutics-$0.46N/AN/AN/AN/AN/A5/7/2026Q1 2026QTTBQ32 Bio-$0.68-$0.54+$0.14-$0.54$39.74 millionN/A3/30/2026Q4 2025JSPRJasper Therapeutics-$0.79-$0.3250+$0.4650-$0.32N/AN/A3/10/2026Q4 2025QTTBQ32 Bio-$1.06$3.65+$4.71$4.58N/A$53.74 million2/27/2026Q4 2025ALDXAldeyra Therapeutics-$0.14-$0.1074+$0.0326-$0.10$24.25 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALDXAldeyra TherapeuticsN/AN/AN/AN/AN/AETHZFlag Ship AcquisitionN/AN/AN/AN/AN/AJSPRJasper TherapeuticsN/AN/AN/AN/AN/AQTTBQ32 BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDXAldeyra TherapeuticsN/A2.582.58ETHZFlag Ship Acquisition1.1110.0710.07JSPRJasper TherapeuticsN/A2.622.62QTTBQ32 Bio0.084.854.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDXAldeyra Therapeutics59.71%ETHZFlag Ship Acquisition4.07%JSPRJasper Therapeutics79.85%QTTBQ32 Bio31.32%Insider OwnershipCompanyInsider OwnershipALDXAldeyra Therapeutics8.50%ETHZFlag Ship Acquisition15.10%JSPRJasper Therapeutics4.60%QTTBQ32 Bio40.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALDXAldeyra Therapeutics1060.32 million55.19 millionOptionableETHZFlag Ship Acquisition719.01 million16.14 millionN/AJSPRJasper Therapeutics2028.00 million26.71 millionOptionableQTTBQ32 Bio3915.63 million9.38 millionN/AJSPR, ALDX, ETHZ, and QTTB HeadlinesRecent News About These CompaniesFY2029 Earnings Forecast for Q32 Bio Issued By HC WainwrightMay 6 at 8:20 AM | marketbeat.comRegulatory Compliance Risks: Q32 Bio Warns of Internal Control Challenges Under Sarbanes-Oxley and Potential Impact on InvestorsMay 6 at 2:11 AM | tipranks.comQ32 Bio's (QTTB) Buy Rating Reaffirmed at HC WainwrightMay 5 at 12:59 PM | marketbeat.comQ32 Bio (NASDAQ:QTTB) Announces Earnings Results, Beats Estimates By $0.14 EPSMay 5 at 12:05 PM | marketbeat.comQ32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 5 at 6:59 AM | prnewswire.comQ32 Bio (QTTB) Expected to Announce Quarterly Earnings on ThursdayApril 30, 2026 | marketbeat.comQ32 Bio (NASDAQ:QTTB) Trading Down 3.8% - What's Next?April 30, 2026 | marketbeat.comQ32 Bio Expands ATM Offering With New $75M ProspectusApril 24, 2026 | tipranks.comQ32 Bio Inc. Common Stock (QTTB) Insider ActivityApril 18, 2026 | nasdaq.comQ32 Bio to Participate in the 25th Annual Needham Virtual Healthcare ConferenceApril 8, 2026 | prnewswire.comQ32 Bio (NASDAQ:QTTB) Shares Up 4.6% - Should You Buy?April 8, 2026 | marketbeat.comDoes Q32 Bio (QTTB) Have the Potential to Rally 97.66% as Wall Street Analysts Expect?March 30, 2026 | zacks.comQ32 Bio: Bempikibart Keeps The Alopecia Areata Bull Case AliveMarch 30, 2026 | seekingalpha.comBest Momentum Stocks to Buy for March 27thMarch 27, 2026 | zacks.comNew Strong Buy Stocks for March 27thMarch 27, 2026 | zacks.comQ32 Bio (QTTB) Upgraded to Strong Buy: Here's What You Should KnowMarch 19, 2026 | zacks.comBest Momentum Stocks to Buy for March 19thMarch 19, 2026 | zacks.comNew Strong Buy Stocks for March 19thMarch 19, 2026 | zacks.comBest Momentum Stocks to Buy for March 13thMarch 13, 2026 | zacks.comWall Street Analysts See a 103.55% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?March 13, 2026 | zacks.comNew Strong Buy Stocks for March 13thMarch 13, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJSPR, ALDX, ETHZ, and QTTB Company DescriptionsAldeyra Therapeutics NASDAQ:ALDX$1.76 +0.04 (+2.03%) As of 02:58 PM Eastern This is a fair market value price provided by Massive. Learn more.Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Flag Ship Acquisition NASDAQ:ETHZ$4.91 -0.58 (-10.56%) As of 05/5/20261180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.Jasper Therapeutics NASDAQ:JSPR$0.96 -0.01 (-1.07%) As of 02:57 PM Eastern This is a fair market value price provided by Massive. Learn more.Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.Q32 Bio NASDAQ:QTTB$5.21 +0.07 (+1.44%) As of 02:57 PM Eastern This is a fair market value price provided by Massive. Learn more.Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage Years in the Making, AMD’s Upside Movement Has Just Begun Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Pinterest Pins a Profit Play To Its Mood Board Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
